Comparison of the diuretic effects of chemically diverse kappa opioid agonists in rats: nalfurafine, U50,488H, and salvinorin A
Kappa opioid receptor agonists induce water diuresis in animals and humans. We investigated the effects of s.c. nalfurafine, U50,488H, salvinorin A, and its longer-acting analog, 2-methoxymethyl-salvinorin B (MOM-sal B), on urinary output and sodium excretion over 5 h in euvolemic rats. Nalfurafine (0.005–0.02 mg/kg), U50,488H (0.1–10 mg/kg), and MOM-sal B (0.625–5 mg/kg) induced diuresis dose-dependently. Systemically (0.1–10 mg/kg) or centrally (50 μg, i.c.v.) administered salvinorin A was ineffective. 5′-Guanidinonaltrindole, a kappa receptor antagonist, inhibited nalfurafine- and MOM-sal B-induced diuresis. Nalfurafine and MOM-sal B had no effect on arginine vasopressin levels, measured at 2 h. Tolerance did not develop to the diuresis accompanying subchronic administration of nalfurafine (0.02 mg/kg). On the basis of our work, we (a) promote nalfurafine as a candidate diuretic to relieve water retention and (b) highlight salvinorin A as a kappa agonist that does not cause diuresis, probably because of its short duration of action.
KeywordsNalfurafine U50,488H Salvinorin A 2-Methoxymethyl-salvinorin B GNTI Diuresis
We thank Dr. Concetta Harakal for valuable comments and Drs. Ellen M. Unterwald and Shane A. Perrine for help in measuring cAMP levels. This study was supported by T32DA07237 from the National Institute on Drug Abuse.
- Ansonoff MA, Zhang J, Czyzyk T, Rothman RB, Stewart J, Xu H, Zjwiony J, Siebert DJ, Yang F, Roth BL, Pintar JE (2006) Antinociceptive and hypothermic effects of salvinorin A are abolished in a novel strain of κ-opioid receptor-1 knockout mice. J Pharmacol Exp Ther 318:641–648PubMedCrossRefGoogle Scholar
- Ashton N, Balment RJ, Blackburn TP (1989) Kappa-opioid-receptor agonists modulate the renal excretion of water and electrolytes in anaesthetized rats. Br J Pharmacol 99:181–185Google Scholar
- Béguin C, Potter DN, DiNieri JA, Munro TA, Richards MR, Paine TA, Berry L, Zhao Z, Roth BL, Xu W, Liu-Chen LY, Carlezon WA Jr, Cohen BM (2008) N-methylacetamide analog of salvinorin A: a highly potent and selective kappa-opioid agonist with oral efficacy. J Pharmacol Exp Ther 324:188–195PubMedCrossRefGoogle Scholar
- Gottlieb HB, Varner KJ, Kenigs VA, Cabral AM, Kapusta DR (2005) Differential cardiovascular and renal responses produced by microinjection of the κ-opioid U-50488H [(trans-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-benzene-acetamide)methane sulfonate] into subregions of the paraventricular nucleus. J Pharmacol Exp Ther 312:678–685PubMedCrossRefGoogle Scholar
- Huidobro-Toro JP, Parada S (1985) Kappa-opiates and urination: pharmacological evidence for an endogenous role of the kappa-opiate receptor in fluid and electrolyte balance. Eur J Pharmacol 107:1–10Google Scholar
- Inan S, Cowan A (2006a) Agmatine-induced stereotyped scratching in mice is antagonized by nalfurafine, a kappa opioid agonist. Pharmacologist 48:38Google Scholar
- Wang Y, Tang K, Inan S, Siebert D, Holzbrabe U, Lee DY, Huang P, Li JG, Cowan A, Liu-Chen LY (2005) Comparison of pharmacological activities of three distinct κ ligands (salvinorin A, TRK-820 and 3FLB) on κ opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther 312:220–230PubMedCrossRefGoogle Scholar